Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this observational study is to understand real-world oral anticoagulants (OAC) (warfarin, apixaban, dabigatran, edoxaban and rivaroxaban) usage for non-valvular atrial fibrillation (NVAF) patients.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Cohort 1 | Non-valvular atrial fibrillation (NVAF) participants receiving oral anticoagulant - Warfarin | ||
| Cohort 2 | NVAF participants receiving oral anticoagulant - Apixaban | ||
| Cohort 3 | NVAF participants receiving oral anticoagulant - Dabigatran | ||
| Cohort 4 | NVAF participants receiving oral anticoagulant - Edoxaban | ||
| Cohort 5 | NVAF participants receiving oral anticoagulant - Rivaroxaban | ||
| Cohort 6 | NVAF participants not receiving oral anticoagulants |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Specialization of the treating physician | At Baseline | |
| Distribution of socio-demographic characteristics of NVAF participants: Age group | At Baseline | |
| Distribution of socio-demographic characteristics of NVAF participants: Gender | At Baseline | |
| Distribution of socio-demographic characteristics of NVAF participants: Body weight | At Baseline | |
| Distribution of socio-demographic characteristics of NVAF participants: Height | At Baseline | |
| Distribution of socio-demographic characteristics of NVAF participants: Body mass index (BMI) | At Baseline | |
| Distribution of outcomes of NVAF participants: Drinking information | At Baseline | |
| Distribution of outcomes of NVAF participants: Smoking information | At Baseline | |
| Distribution of outcomes of NVAF participants: Internal medical device information | At Baseline | |
| Distribution of outcomes of NVAF participants: Degree of life freedom | At Baseline |
Not provided
Not provided
Inclusion Criteria:
• Participants received medical treatment for NVAF between 10-Jan-2012 and 31-Aug-2020.
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria apply.
Not provided
Not provided
Not provided
The study population will consist of an estimated 12,000 Non-valvular atrial fibrillation (NVAF) participants' medical charts that will fulfill the study eligibility criteria.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Bristol-Myers Squibb | Bristol-Myers Squibb | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Local Institution | Tokyo | 1070052 | Japan |
Not provided
| Label | URL |
|---|---|
| BMS Clinical Trial Information | View source |
| Investigator Inquiry Form | View source |
| FDA Safety Alerts and Recalls |
Not provided
Not provided
Not provided
Not provided
Not provided
| Distribution of outcomes of NVAF participants: Hospitalization/outpatient status | At Baseline |
| Distribution of outcomes of NVAF participants: Systolic and diastolic blood pressure | At Baseline |
| Distribution of outcomes of NVAF participants: Pulse rate | At Baseline |
| Distribution of clinical characteristics of NVAF participants: Risk factors for stroke | At Baseline |
| Distribution of clinical characteristics of NVAF participants: Risk factors for bleeding | At Baseline |
| Distribution of clinical characteristics of NVAF participants: Comorbidities | At Baseline |
| Distribution of outcomes of NVAF participants: OAC prescription and administration status | At Baseline |
| Distribution of medication prescribed during baseline: angiotensin-converting enzyme inhibitor (ACE) | At Baseline |
| Distribution of medication prescribed during baseline: angiotensin-receptor blocker (ARB) | At Baseline |
| Distribution of medication prescribed during baseline: calcium antagonist | At Baseline |
| Distribution of medication prescribed during baseline: Antiarrhythmic drug | At Baseline |
| Distribution of medication prescribed during baseline: Statin | At Baseline |
| Distribution of medication prescribed during baseline: proton pump inhibitor (PPI) | At Baseline |
| Distribution of medication prescribed during baseline: H2-receptor antagonist | At Baseline |
| Distribution of medication prescribed during baseline: aspirin | At Baseline |
| Distribution of medication prescribed during baseline: P2Y12 inhibitor | At Baseline |
| Distribution of medication prescribed during baseline: Other antiplatelet drugs | At Baseline |
| Distribution of medication prescribed during baseline: Other anticoagulants | At Baseline |
| Distribution of medication prescribed during baseline: P-glycoprotein inhibitor | At Baseline |
| ID | Term |
|---|---|
| D001281 | Atrial Fibrillation |
| ID | Term |
|---|---|
| D001145 | Arrhythmias, Cardiac |
| D006331 | Heart Diseases |
| D002318 | Cardiovascular Diseases |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided